Pharmaceutical News

RSS

Gilenya prevents and reverses symptoms of ventricular hypertrophy

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

30 Jan 2012

FDA approves Lannett's ANDA for Hydrochlorothiazide Capsules, 12.5 mg

Lannett Company, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrochlorothiazide Capsules, 12.5 mg.

30 Jan 2012

Cell Therapeutics voluntarily withdraws Pixuvri NDA for NHL

Cell Therapeutics, Inc. announced today that it has voluntarily withdrawn its New Drug Application for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy.

30 Jan 2012

Inlyta receives FDA approval for treatment of advanced kidney cancer

The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.

30 Jan 2012

FTC terms Omnicare's proposed acquisition of PharMerica illegal

The Federal Trade Commission issued a complaint to block Omnicare, Inc.'s hostile acquisition of rival long-term care pharmacy provider PharMerica Corporation, alleging that the combination of the two largest U.S. long-term care pharmacies would harm competition and enable Omnicare to raise the price of drugs for Medicare Part D consumers and others.

30 Jan 2012

Scientists develop new vaccine to treat cancer at pre-clinical level

Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumours.

27 Jan 2012

New discovery paves way for genetic screening test

Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors.

27 Jan 2012

DWH signs collaboration agreement with CPDD

Developing World Health (DWH), a leading medical charity based in Stirlingshire, Scotland and committed to developing effective treatments for neglected tropical diseases, has signed a collaboration agreement with the internationally respected Consortium for Parasitic Drug Development (CPDD), based at The University of North Carolina at Chapel Hill.

27 Jan 2012

Rapid discontinuation of prednisone after kidney transplant can help prevent side effects

Rapid discontinuation of the immunosuppressive steroid prednisone after a kidney transplant can help prevent serious side effects, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

27 Jan 2012

New system safe, effective in delivering CsA to organ transplant patients

A new system for delivering a drug to organ transplant patients, which could avoid the risk of harmful side effects, is being developed by scientists at the University of Strathclyde in Glasgow.

27 Jan 2012

MSF warns about lack of access to antiretroviral treatment in DRC, urges government, donor action

"Eighty-six percent of HIV-positive people in the Democratic Republic of Congo [DRC] have no access to antiretrovirals, medical charity Doctors Without Borders said Wednesday," calling the "conditions of access to care for people living with HIV/AIDS ... catastrophic," Agence France-Presse reports.

27 Jan 2012

LEO Pharma receives FDA approval for Picato topical gel to treat AK

LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis.

27 Jan 2012

FDA approves UCB's Keppra for treatment of partial onset seizures in infants

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in the treatment of partial onset seizures in adults and children one month of age and older with epilepsy.

27 Jan 2012

Universal access to HIV treatment can be achieved

"Thirty years after AIDS made its deadly debut, a future without the disease is finally within reach," a Boston Globe editorial states, adding, "But just as science is on the verge of winning the battle, financial resources and political will are flagging."

25 Jan 2012

Thomson CompuMark announces launch of Global Pharmaceutical Search

Thomson CompuMark, the global leader in trademark searching and brand protection solutions and part of Thomson Reuters, today announced the launch of Global Pharmaceutical Search, a new service providing targeted, global trademark intelligence in a single online report.

25 Jan 2012

Glanbia Nutritionals, ChromaDex sign LOI for pTeroPure

ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of its branded patent-pending pterostilbene, pTeroPure, announced today it has signed a letter of intent with Glanbia Nutritionals (NA), Inc., a global ingredient and micronutrient premix company, for the distribution of pTeroPure. Glanbia Nutritionals will serve as the primary distributor of pTeroPure in North America.

25 Jan 2012

Genetic variation predisposes children to complications linked with second-generation anti-psychotics

Researchers have found a genetic variation predisposing children to six-times greater risk of developing metabolic syndrome when taking second-generation anti-psychotic medications. Metabolic syndrome is a cluster of conditions that are risk factors for cardiovascular disease.

25 Jan 2012

GUMC licenses worldwide rights of 'theranostic' to BioMetrx

Georgetown University Medical Center (GUMC) has licensed worldwide rights of a potential novel cancer therapy and diagnostic, or "theranostic," to BioMetrx, LLC. The agent was invented by two Georgetown researchers.

25 Jan 2012

AstraZeneca donation to benefit poor and uninsured Americans

AstraZeneca, the global biopharmaceutical company, has donated $3.8 million worth of prescription medicines to AmeriCares for chronically ill Americans who rely on safety net clinics for their medical care. The donation is one of the largest AmeriCares received in the past year for its domestic aid deliveries.

25 Jan 2012

Low doses of DHEA may help relieve menopausal symptoms in women

Leading age management facility, Cenegenics Carolinas, located in Charleston and Charlotte is encouraged by a recent study suggesting low doses of the hormone DHEA may help sexual function and menopausal symptoms in women.

25 Jan 2012